<DOC>
	<DOCNO>NCT00575562</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability KRN330 patient relapse refractory advanced metastatic colorectal cancer .</brief_summary>
	<brief_title>Phase I Study KRN330 Monoclonal Antibody Patients With Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Have histologically confirm colorectal cancer advance metastatic measurable assessable disease . 2 . Are candidate surgically curative procedure . 3 . Have progress despite , intolerant , appropriate current therapy . 1 . Have active , uncontrolled infection . 2 . Have know suspected cerebral metastasis . 3 . Have myocardial infarction ( MI ) cerebrovascular accident ( CVA ) within last 6 month ; meet criterion AHA class III IV congestive heart failure ( CHF ) . 4 . Have significant concurrent disease illness would interfere interpretation study result . 5 . Pregnant breastfeed woman male female patient agree use effective contraceptive method ( ) study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>